Adlai Nortye Ltd. (NASDAQ:ANL) Sees Significant Growth in Short Interest

Adlai Nortye Ltd. (NASDAQ:ANL) was the target of a significant growth in short interest during the month of February. As of February 28th, there was short interest totalling 7,200 shares, a growth of 89.5% from the February 13th total of 3,800 shares. Currently, 0.0% of the shares of the stock are sold short. Based on an average daily trading volume, of 8,600 shares, the days-to-cover ratio is presently 0.8 days.

Adlai Nortye Trading Up 1.7 %

Shares of ANL stock opened at $2.33 on Friday. The firm’s 50 day moving average is $2.15 and its 200-day moving average is $2.25. Adlai Nortye has a 1 year low of $1.85 and a 1 year high of $17.48.

About Adlai Nortye

Adlai Nortye Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of cancer therapies in the United States and Mainland China. Its lead product is AN2025, a pan-phosphoinositide 3-kinase inhibitor, which is in Phase III clinical trial for the treatment of recurrent or metastatic head and neck squamous cell carcinomas.